Alaunos Therapeutics
TCRT
30 hedge funds and large institutions have $137K invested in Alaunos Therapeutics in 2024 Q4 according to their latest regulatory filings, with 6 funds opening new positions, 2 increasing their positions, 12 reducing their positions, and 5 closing their positions.
20% more first-time investments, than exits
New positions opened: 6 | Existing positions closed: 5
3% more funds holding
Funds holding: 29 → 30 (+1)
7.5% less ownership
Funds ownership: 12% → 4.51% (-7.5%)
78% less capital invested
Capital invested by funds: $623K → $137K (-$486K)
83% less repeat investments, than reductions
Existing positions increased: 2 | Existing positions reduced: 12
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
UBS Group
Zurich,
Switzerland
|
+$15.2K |
| 2 |
Citigroup
New York
|
+$3.55K |
| 3 |
TRCT
Tower Research Capital (TRC)
New York
|
+$1.13K |
| 4 |
Royal Bank of Canada
Toronto,
Ontario, Canada
|
+$240 |
| 5 |
TSMHT
Thurston Springer Miller Herd & Titak
Indianapolis,
Indiana
|
+$47 |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
MP
MSD Partners
New York
|
-$325K |
| 2 |
Vanguard Group
Malvern,
Pennsylvania
|
-$54.2K |
| 3 |
Geode Capital Management
Boston,
Massachusetts
|
-$2.48K |
| 4 |
BlackRock
New York
|
-$1.96K |
| 5 |
FDCDDQ
Federation des caisses Desjardins du Quebec
Levis,
Quebec, Canada
|
-$765 |
TCRT Hedge Fund Activity: Q4 2024 in Review
30 of the 7,592 institutional investors tracked by Wall St. Rank reported a position in Alaunos Therapeutics (TCRT) for Q4 2024, worth a combined $137K — down 78% from $623K a quarter earlier.
Buyers outnumbered sellers: 6 funds opened new TCRT positions and 5 closed out — a net gain of 1 holder — while 2 added to existing stakes and 12 trimmed.
The largest buyer was UBS Group, adding an estimated $15.2K. The largest seller was MSD Partners, exiting entirely with an estimated $325K sold.
- 30 institutional investors held Alaunos Therapeutics (TCRT) as of Q4 2024, up from 29 in Q3 2024.
- Funds reported $137K of Alaunos Therapeutics stock for Q4 2024, down 78% quarter-over-quarter.
- 6 funds opened new Alaunos Therapeutics positions in Q4 2024 and 5 closed out, a net change of +1 holder.
- The largest Alaunos Therapeutics buyer in Q4 2024 was UBS Group, an estimated $15.2K added.
- The largest Alaunos Therapeutics seller in Q4 2024 was MSD Partners, an estimated $325K sold.
Based on aggregated 13F filings for Q4 2024.